These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8227482)

  • 1. Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteers.
    Caccia S; Confalonieri S; Guiso G; Lucca U; Parma E; Guido M; Tettamanti M; Tiraboschi P; Spagnoli A
    J Clin Pharmacol; 1993 Sep; 33(9):845-50. PubMed ID: 8227482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose pharmacokinetics and safety of a potential memory-enhancing compound, CL 275,838, in healthy male volunteers.
    Caccia S; Confalonieri S; Guiso G; Lucca U; Parma E; Guido M; Tettamanti M; Tiraboschi P; Spagnoli A
    J Clin Pharmacol; 1994 Jul; 34(7):748-53. PubMed ID: 7929869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms.
    Caccia S; Confalonieri S; Guiso G; Bernasconi P; Cagnotto A; Skorupska M; Mennini T
    Psychopharmacology (Berl); 1994 Aug; 115(4):502-8. PubMed ID: 7871095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
    Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
    Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
    Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects.
    Srinivas NR; Shyu WC; Gleason C; Schuster A; Greene DS; Barbhaiya RH
    Clin Pharmacol Ther; 1997 Oct; 62(4):408-16. PubMed ID: 9357392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third-generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers.
    Noh YS; Yoon S; Kim SR; Lee KT; Jang IJ
    Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):370-381. PubMed ID: 31125491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
    Krishnaswami S; Boy M; Chow V; Chan G
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration.
    Raghoebar M; Mak M; Cournot A; Pistorius MC; Van Harten J; Roseboom H
    Br J Clin Pharmacol; 1990 Dec; 30(6):879-83. PubMed ID: 2288834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R; Högemann AM; Sunzel M; Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic.
    Beer B; Ieni JR; Wu WH; Clody D; Amorusi P; Rose J; Mant T; Gaudreault J; Cato A; Stern W
    J Clin Pharmacol; 1994 Apr; 34(4):335-44. PubMed ID: 8006201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of age on the pharmacokinetics of solifenacin in men and women.
    Krauwinkel WJ; Smulders RA; Mulder H; Swart PJ; Taekema-Roelvink ME
    Int J Clin Pharmacol Ther; 2005 May; 43(5):227-38. PubMed ID: 15906588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
    Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
    J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers.
    Muirhead GJ; Faulkner S; Harness JA; Taubel J
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):37S-43S. PubMed ID: 11879258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of mizolastine.
    Lebrun-Vignes B; Diquet B; Chosidow O
    Clin Pharmacokinet; 2001; 40(7):501-7. PubMed ID: 11510627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.